Targeting the Angiopoietin-2/Tie-2 axis in conjunction with VEGF signal interference.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Cancer Letters

• Publication date

  2016-10-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.canlet.2014.09.035PMID 25312939PMCID PMC4394020
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Results from the first-in-human (FIH) phase I study of RO5520985 (RG7221), a novel bispecific human anti-ANG-2/anti-VEGF-A antibody, administered as an intravenous infusion to patients with advanced solid tumors.

  2014cited by this paper
• Suppression of angiogenesis and tumor growth in vitro and in vivo using an anti-angiopoietin-2 single-chain antibody

  2014cited by this paper
• Exogenous administration of protease-resistant, non-matrix-binding IGFBP-2 inhibits tumour growth in a murine model of breast cancer

  2014cited by this paper
• CP-673451, a platelet-derived growth-factor receptor inhibitor, suppresses lung cancer cell proliferation and migration

  2014cited by this paper
• Tie1 deletion inhibits tumor growth and improves angiopoietin antagonist therapy.

  2014cited by this paper
• Can Vascular Endothelial Growth Factor and Microvessel Density Be Used as Prognostic Biomarkers for Colorectal Cancer? A Systematic Review and Meta-Analysis

  2014cited by this paper
• VEGF and Notch in tip and stalk cell selection.

  2013cited by this paper
• Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition.

  2013cited by this paper
• Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy

  2013cited by this paper
• Image-Based Brachytherapy in Cervical Cancer: Review and Experiences in Faculty of Medicine, Chiang Mai University

  2013cited by this paper
• Structural basis for angiopoietin-1–mediated signaling initiation

  2013cited by this paper
• Combined Ang-2 and VEGF Targeting Therapies in Renal Cell Carcinoma

  2013cited by this paper
• Phase I study of anti-PlGF monoclonal antibody (mAb) RO5323441 (RO) and anti-VEGF mab bevacizumab (BV) in patients with recurrent glioblastoma (GBM).

  2013cited by this paper
• Angiopoietin-2 Axis Inhibitors: Current Status and Future Considerations for Cancer Therapy

  2013cited by this paper
• VE-PTP regulates VEGFR2 activity in stalk cells to establish endothelial cell polarity and lumen formation

  2013cited by this paper
• Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms

  2013cited by this paper
• Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies.

  2012cited by this paper
• Concordant release of glycolysis proteins into the plasma preceding a diagnosis of ER+ breast cancer.

  2012cited by this paper
• Side effects of anti-angiogenic drugs.

  2012cited by this paper
• Enhanced Antitumor Efficacy of a Vascular Disrupting Agent Combined with an Antiangiogenic in a Rat Liver Tumor Model Evaluated by Multiparametric MRI

  2012cited by this paper
• Anti‐angiogenic Therapy: Concept to Clinic

  2012cited by this paper
• Angiogenesis : biology and pathology

  2012cited by this paper
• FGF Receptor Inhibitors: Role in Cancer Therapy

  2012cited by this paper
• Inhibition of endothelial/smooth muscle cell contact loss by the investigational angiopoietin-2 antibody MEDI3617.

  2012cited by this paper
• Angiogenesis Inhibitors and Radiation in Multimodality Cancer Therapy: Preclinical and Clinical Studies

  2012cited by this paper
• Anti-VEGF/VEGFR therapy for cancer: reassessing the target.

  2012cited by this paper
• Transcriptome and Network Changes in Climbers at Extreme Altitudes

  2012cited by this paper
• Combining Bevacizumab with Radiation or Chemoradiation for Solid Tumors: A Review of the Scientific Rationale, and Clinical Trials.

  2012cited by this paper
• Bevacizumab in the Treatment of Metastatic Breast Cancer: Friend or Foe?

  2012cited by this paper
• Phase I Trial of Combretastatin A4 Phosphate (CA4P) in Combination with Bevacizumab in Patients with Advanced Cancer

  2012cited by this paper
• Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling.

  2012cited by this paper
• VEGF Inhibition, Hypertension, and Renal Toxicity

  2012cited by this paper
• MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models.

  2012cited by this paper
• Anti-VEGF therapies in the clinic.

  2012cited by this paper
• Targeting the Notch pathway: twists and turns on the road to rational therapeutics.

  2012cited by this paper
• Tie1 regulates the Tie2 agonistic role of angiopoietin-2 in human lymphatic endothelial cells.

  2012cited by this paper
• Potent Inhibition of Angiogenesis by the IGF-1 Receptor-Targeting Antibody SCH717454 Is Reversed by IGF-2

  2011cited by this paper
• Prognostic significance of vascular endothelial growth factor expression in gastric carcinoma: a meta-analysis

  2011cited by this paper
• Beyond VEGF: Inhibition of the Fibroblast Growth Factor Pathway and Antiangiogenesis

  2011cited by this paper
• Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells.

  2011cited by this paper
• Angiopoietin-2 TIEs Up Macrophages in Tumor Angiogenesis

  2011cited by this paper
• Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity

  2011cited by this paper
• Meta-analysis of immunohistochemical prognostic markers in resected pancreatic cancer

  2011cited by this paper
• The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents.

  2011cited by this paper
• TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice.

  2011cited by this paper
• Drug Penetration and Therapeutic Resistance

  2010cited by this paper
• Context-Dependent Role of Angiopoietin-1 Inhibition in the Suppression of Angiogenesis and Tumor Growth: Implications for AMG 386, an Angiopoietin-1/2–Neutralizing Peptibody

  2010cited by this paper
• Effects of angiopoietins-1 and -2 on the receptor tyrosine kinase Tie2 are differentially regulated at the endothelial cell surface

  2010influential reference
• PlGF blockade does not inhibit angiogenesis during primary tumor growth.

  2010cited by this paper
• A Human Monoclonal Anti-ANG2 Antibody Leads to Broad Antitumor Activity in Combination with VEGF Inhibitors and Chemotherapy Agents in Preclinical Models

  2010cited by this paper
• Pathways mediating VEGF-independent tumor angiogenesis.

  2010cited by this paper
• Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates.

  2010cited by this paper
• Tie1-Tie2 interactions mediate functional differences between angiopoietin ligands.

  2010cited by this paper
• Double antiangiogenic protein, DAAP, targeting VEGF-A and angiopoietins in tumor angiogenesis, metastasis, and vascular leakage.

  2010cited by this paper
• Angiopoietin-2 Promotes Disease Progression of Neuroendocrine Tumors

  2010cited by this paper
• Combining Antiangiogenic Drugs with Vascular Disrupting Agents Rationale and Mechanisms of Action

  2010cited by this paper
• Chemical generation of bispecific antibodies

  2010cited by this paper
• Tumor and Host-Mediated Pathways of Resistance and Disease Progression in Response to Antiangiogenic Therapy

  2009influential reference
• The role of the Angiopoietins in vascular morphogenesis

  2009cited by this paper
• Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis

  2009cited by this paper
• Angiopoietin-2 Levels Are Associated with Disease Progression in Metastatic Malignant Melanoma

  2009cited by this paper
• Prognostic Value of Vascular Endothelial Growth Factor Expression in Patients with Lung Cancer: A Systematic Review with Meta-Analysis

  2009cited by this paper
• Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels.

  2009cited by this paper
• Control of vascular morphogenesis and homeostasis through the angiopoietin–Tie system

  2009cited by this paper
• Tumor‐associated macrophages (TAM) as major players of the cancer‐related inflammation

  2009cited by this paper
• Angiopoietin-2 Exocytosis Is Stimulated by Sphingosine-1-Phosphate in Human Blood and Lymphatic Endothelial Cells

  2009cited by this paper
• The angiopoietin 1/angiopoietin 2 balance as a prognostic marker in primary glioblastoma multiforme.

  2009cited by this paper
• Shear stress-induced activation of the AMP-activated protein kinase regulates FoxO1a and angiopoietin-2 in endothelial cells.

  2008cited by this paper
• Modes of resistance to anti-angiogenic therapy

  2008influential reference
• The role of the EGFR signaling in tumor microenvironment

  2008cited by this paper
• Angiogenesis: an integrative approach from science to medicine

  2008cited by this paper
• Angiopoietins assemble distinct Tie2 signalling complexes in endothelial cell–cell and cell–matrix contacts

  2008cited by this paper
• Hypoxic regulation of angiogenesis by HIF-1

  2008cited by this paper
• Vascular Permeability/Vascular Endothelial Growth Factor

  2008influential reference
• Angiogenesis and Vascular Remodeling in Inflammation and Cancer: Biology and Architecture of the Vasculature

  2008cited by this paper
• The role of hypoxia-inducible factors in tumorigenesis

  2008cited by this paper
• Differential function of Tie2 at cell–cell contacts and cell–substratum contacts regulated by angiopoietin-1

  2008cited by this paper
• Angiopoietin-1 prevents VEGF-induced endothelial permeability by sequestering Src through mDia.

  2008cited by this paper
• Dual targeting of tumor vasculature: combining Avastin and vascular disrupting agents (CA4P or OXi4503).

  2008cited by this paper
• Tie2-expressing monocytes: regulation of tumor angiogenesis and therapeutic implications.

  2007cited by this paper
• Angiogenesis: an organizing principle for drug discovery?

  2007cited by this paper
• Delta-like 4/Notch Signaling and Its Therapeutic Implications

  2007cited by this paper
• Serum angiopoietin-2 as a clinical marker for lung cancer.

  2007cited by this paper
• Scheduling of Radiation with Angiogenesis Inhibitors Anginex and Avastin Improves Therapeutic Outcome via Vessel Normalization

  2007cited by this paper
• Angiopoietins in malignancy.

  2007cited by this paper
• PDGF receptors as targets in tumor treatment.

  2007cited by this paper
• Abnormal Microvasculature and Defective Microcirculatory Function in Solid Tumors

  2006cited by this paper
• Antiangiogenic Therapy: A Universal Chemosensitization Strategy for Cancer?

  2006cited by this paper
• Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis.

  2006cited by this paper
• Interaction between Tie receptors modulates angiogenic activity of angiopoietin2 in endothelial progenitor cells.

  2006cited by this paper
• Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis

  2006cited by this paper
• Drug penetration in solid tumours

  2006cited by this paper
• Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis

  2006cited by this paper
• Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies.

  2006cited by this paper
• Angiopoietin 2 expression is related to histological grade, vascular density, metastases, and outcome in prostate cancer

  2005cited by this paper
• Differentiation and definition of vascular-targeted therapies.

  2005cited by this paper
• Vascular targeting therapies for treatment of malignant disease

  2005cited by this paper
• The Tie-2 ligand Angiopoietin-2 destabilizes quiescent endothelium through an internal autocrine loop mechanism

  2005cited by this paper
• Antiangiogenic therapy for cancer: current and emerging concepts.

  2005cited by this paper
• Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis.

  2004cited by this paper

• Endothelial miR-7052 Safeguards Blood–Brain Barrier Integrity During Endotoxemia by Co-repressing ANGPT2 and PDE5A

  2026cites this paper
• Emerging strategies to overcome chemotherapy resistance in breast cancer

  2025cites this paper
• Matter of Fat: Cancer‐Associated Adipocytes as Mediators of Tumor Progression and Immune Evasion

  2025cites this paper
• Angiopausin® and Angiopoietin: Unveiling New Mechanisms in Rosacea Treatment through Kinetic Erythema Analysis with the AAREA® Algorithm.

  2025cites this paper
• Progress in the Application of Nanomaterials in Tumor Treatment

  2025cites this paper
• Progress in targeting tumor-associated macrophages in cancer immunotherapy

  2025cites this paper
• PKM2 regulates angiogenic activation via ANGPT2 in endothelial cells

  2025cites this paper
• Lenvatinib Plus Pembrolizumab Versus Chemotherapy in Advanced Endometrial Cancer: Efficacy and Safety Insights

  2025cites this paper
• Endothelial Protein Changes Indicative of Endometriosis in Unexplained Infertility, an Exploratory Study

  2025cites this paper
• Extracellular Vesicle-Associated Angiopoietin-2 and Cell Migration-Inducing Protein in Lung Cancer Progression and Brain Metastases

  2025cites this paper
• Inhibition of Endothelial Cell Tube Formation by Anti-Vascular Endothelial Growth Factor/Anti-Angiopoietin-2 RNA Nanoparticles

  2025cites this paper
• miR-205: A dual regulator of angiogenesis in health and disease (Review)

  2025cites this paper
• FGF-2–Overexpressing Adipose-Derived Stem Cells as a Paracrine Platform for Angiogenesis-Driven Tissue Regeneration

  2025cites this paper
• Research Progress Regarding the Use of Single-Cell Sequencing Technology in Analyzing Tumor Endothelial Cell Pathophysiology

  2025cites this paper
• Arginine methylation in cancer: mechanisms and therapeutic implications

  2025cites this paper
• Decoding heterogeneous and coordinated tissue architecture in glioblastoma using spatial transcriptomics

  2024cites this paper
• MiR-221-5p regulates blood–brain barrier dysfunction through the angiopoietin-1/-2/Tie-2 signaling axis after subarachnoid hemorrhage

  2024cites this paper
• The Role of Immune Cells and Signaling Pathways in Diabetic Eye Disease: A Comprehensive Review

  2024cites this paper
• [Current views on pathogenesis and treatment of neovascular glaucoma].

  2024cites this paper
• The mechanism and therapeutic strategies for neovascular glaucoma secondary to diabetic retinopathy

  2023cites this paper
• Ensemble biomarkers for guiding anti‐angiogenesis therapy for ovarian cancer using deep learning

  2023cites this paper
• Expression of Angiopoietin-2 in Lung Tissue of Juvenile SD Rats with Lipopolysaccharide-Induced Acute Lung Injury and the Role of Ulinastatin

  2023cites this paper
• Glycation of fibronectin impairs angiopoietin-1/Tie-2 signaling through uncoupling Tie-2-α5β1 integrin crosstalk.

  2023cites this paper
• Combination human umbilical cord perivascular and endothelial colony forming cell therapy for ischemic cardiac injury

  2023cites this paper
• miR‐221‐3p targets Ang‐2 to inhibit the transformation of HCMECs to tip cells

  2023cites this paper
• Catalpol Prevents Glomerular Angiogenesis Induced by Advanced Glycation End Products via Inhibiting Galectin-3

  2023cites this paper
• A comprehensive insight into the role of molecular pathways affected by the Angiopoietin and Tie system involved in hematological malignancies' pathogenesis.

  2023cites this paper
• Rethinking the potential and necessity of drug delivery systems in neovascular age-related macular degeneration therapy

  2023cites this paper
• Light Chain Q166C Mutation Permits One‐step Site Specific Conjugation on Monoclonal Antibodies

  2023cites this paper
• Interpretable attention-based deep learning ensemble for personalized ovarian cancer treatment without manual annotations

  2023cites this paper
• Advances in biosynthesis of peptide drugs: Technology and industrialization

  2023cites this paper
• Protective Effects of 4-Trifluoromethyl-(E)-cinnamoyl]-L-4-F-phenylalanine Acid against Chronic Cerebral Hypoperfusion Injury through Promoting Brain-Derived Neurotrophic Factor-Mediated Neurogenesis.

  2022cites this paper
• Tie-2 Expressing Monocytes in The Pathogenesis of Chronic Lymphocytic Leukemia

  2021cites this paper
• Circulating growth factors and cardiac remodeling in the community: The Framingham Heart Study.

  2021cites this paper
• Linalool inhibits the angiogenic activity of endothelial cells by downregulating intracellular ATP levels and activating TRPM8

  2021cites this paper
• Anlotinib suppresses metastasis and multidrug resistance via dual blockade of MET/ABCB1 in colorectal carcinoma cells

  2021cites this paper
• Prognostic role of plasma level of angiopoietin-1, angiopoietin-2, and vascular endothelial growth factor in hepatocellular carcinoma

  2021cites this paper
• Investigation of the hepatic development in the coculture of hiPSCs-derived LSECs and HLCs in a fluidic microenvironment

  2021cites this paper
• Update Overview of the Role of Angiopoietins in Lung Cancer

  2021cites this paper
• Bispecific monoclonal antibodies for targeted immunotherapy of solid tumors: Recent advances and clinical trials.

  2020cites this paper
• Role of angiopoietin-2 in inflammatory autoimmune diseases: A comprehensive review.

  2020cites this paper
• Sex differences in cancer mechanisms

  2020cites this paper
• FOXC2 is a prognostic biomarker and contributes to the growth and invasion of human hepatocellular carcinoma

  2020cites this paper
• Tumor-on-a-chip platform to interrogate the role of macrophages in tumor progression

  2020cites this paper
• miR-205-5p inhibits psoriasis-associated proliferation and angiogenesis: Wnt/β-catenin and mitogen-activated protein kinase signaling pathway are involved.

  2020cites this paper
• Serum IL-8 level as a candidate prognostic marker of response to anti-angiogenic therapy for metastatic colorectal cancer

  2020cites this paper
• Combining 1,4-dihydroxy quininib with Bevacizumab/FOLFOX alters angiogenic and inflammatory secretions in ex vivo colorectal tumors

  2020cites this paper
• Visualizing cancer extravasation: from mechanistic studies to drug development

  2020cites this paper
• Linking Circulating Serum Proteins with Clinical Outcomes in Esophageal Adenocarcinoma—An Emerging Role for Chemokines

  2020cites this paper
• Blood angiopoietin-2 predicts liver angiogenesis and fibrosis in hepatitis C patients

  2020cites this paper
• miR-15a/-16 Inhibit Angiogenesis by Targeting the Tie2 Coding Sequence: Therapeutic Potential of a miR-15a/16 Decoy System in Limb Ischemia

  2019cites this paper
• Improved Oxygen Supply to Multicellular Spheroids Using A Gas-permeable Plate and Embedded Hydrogel Beads

  2019cites this paper
• Angiopoietin 2 signal complexity in cardiovascular disease and cancer.

  2019cites this paper
• Heterogeneity of Vascular Endothelial Cells, De Novo Arteriogenesis and Therapeutic Implications in Pancreatic Neuroendocrine Tumors

  2019cites this paper
• Imbalance of Pro- and Anti-Angiogenic Factors Due to Maternal Vitamin D Deficiency Causes Renal Microvasculature Alterations Affecting the Adult Kidney Function

  2019cites this paper
• Explorer miR-15 a /-16 Inhibit Angiogenesis by Targeting the Tie 2 Coding Sequence : Therapeutic Potential of a miR-15 a / 16 Decoy System in Limb Ischemia

  2019cites this paper
• Dl-3-n-Butylphthalide regulates the Ang-1/Ang-2/Tie-2 signaling axis to promote neovascularization in chronic cerebral hypoperfusion.

  2019cites this paper
• Single-Cell Receptor Quantification of an In Vitro Coculture Angiogenesis Model Reveals VEGFR, NRP1, Tie2, and PDGFR Regulation and Endothelial Heterogeneity

  2019cites this paper
• Potential of Herbal Medicines in Colorectal Carcinoma and Their Mechanism of Action

  2018cites this paper
• Targeted Theranostic Nanoparticles for Brain Tumor Treatment

  2018cites this paper
• NRP-2 in tumor lymphangiogenesis and lymphatic metastasis.

  2018cites this paper
• Capillary rarefaction and altered renal development: the imbalance between pro- and anti-angiogenic factors in response to angiotensin II inhibition in the developing rat kidney

  2018cites this paper
• Selected factors influencing angiogenesis and hematopoietic niche

  2018cites this paper
• Bispecific Antibodies: Formats and Areas of Application

  2018cites this paper
• A history of exploring cancer in context

  2018cites this paper
• Receptor Tyrosine Kinase-Targeted Cancer Therapy

  2018cites this paper
• Bispecific antibodies and their potential for cancer immunotherapy

  2017cites this paper
• Effect of Taoren Quyu Decoction on human endometrial cells and its anti-endometriosis activity in rats.

  2017cites this paper
• [Venolymphatic malformation with bone erosion. An unusual affectation in these lesions].

  2017cites this paper
• Two natural eudesmane-type sesquiterpenes from Laggera alata inhibit angiogenesis and suppress breast cancer cell migration through VEGF- and Angiopoietin 2-mediated signaling pathways.

  2017cites this paper
• TSLP/TSLPR promote angiogenesis following ischemic stroke via activation of the PI3K/AKT pathway.

  2017cites this paper
• CTGF promotes osteosarcoma angiogenesis by regulating miR-543/angiopoietin 2 signaling.

  2017cites this paper
• VEGF, ANGPT1, ANGPT2, and MMP-9 expression in the autologous hematopoietic stem cell transplantation and its impact on the time to engraftment

  2017cites this paper
• All-trans retinoic acid suppresses the angiopoietin-Tie2 pathway and inhibits angiogenesis and metastasis in esophageal squamous cell carcinoma

  2017cites this paper
• Translational Significance for Tumor Metastasis of Tumor-Associated Macrophages and Epithelial–Mesenchymal Transition

  2017cites this paper
• Suppression of KSHV-induced angiopoietin-2 inhibits angiogenesis, infiltration of inflammatory cells, and tumor growth

  2016cites this paper
• In Silico Exploration for Novel Type-I Inhibitors of Tie-2/TEK: The Performance of Different Selection Strategy in Selecting Virtual Screening Candidates

  2016cites this paper
• Effects of definitive chemoradiation on circulating immunologic angiogenic cytokines in head and neck cancer patients

  2016cites this paper
• Identification and Preliminary SAR Analysis of Novel Type-I Inhibitors of TIE-2 via Structure-Based Virtual Screening and Biological Evaluation in in vitro Models

  2015cites this paper
• Tubeimoside-1 suppresses tumor angiogenesis by stimulation of proteasomal VEGFR2 and Tie2 degradation in a non-small cell lung cancer xenograft model

  2015influential citation
• Bispecific antibodies and their applications

  2015cites this paper
• The Angiopoietin—Tie System: Common Signaling Pathways for Angiogenesis, Cancer, and Inflammation

  2015influential citation
• Role of the angiopoietin/Tie system in pregnancy (Review)

  2015cites this paper
• Regulation of Angiogenic Functions by Angiopoietins through Calcium-Dependent Signaling Pathways

  2015cites this paper
• 1 Improvement of oxygen supply to the multicellular 2 spheroids using a gas ‐ permeable plate and embedded 3 hydrogel beads

  year unknowncites this paper